NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. More Details
Solid track record average dividend payer.
Share Price & News
How has NEUCA's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEU is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: NEU's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: NEU exceeded the Polish Healthcare industry which returned 50.1% over the past year.
Return vs Market: NEU exceeded the Polish Market which returned -6.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is NEUCA's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAnnouncing: NEUCA (WSE:NEU) Stock Increased An Energizing 122% In The Last Three Years
2 weeks ago | Simply Wall StDoes NEUCA's (WSE:NEU) CEO Salary Compare Well With Industry Peers?
1 month ago | Simply Wall StNEUCA S.A.'s (WSE:NEU) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Is NEUCA undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NEU (PLN602) is trading below our estimate of fair value (PLN687.75)
Significantly Below Fair Value: NEU is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: NEU is good value based on its PE Ratio (19.4x) compared to the PL Healthcare industry average (41.4x).
PE vs Market: NEU is poor value based on its PE Ratio (19.4x) compared to the Polish market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: NEU is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: NEU is overvalued based on its PB Ratio (3.7x) compared to the PL Healthcare industry average (3.3x).
How is NEUCA forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEU's forecast earnings growth (11.1% per year) is above the savings rate (2.9%).
Earnings vs Market: NEU's earnings (11.1% per year) are forecast to grow slower than the Polish market (18.9% per year).
High Growth Earnings: NEU's earnings are forecast to grow, but not significantly.
Revenue vs Market: NEU's revenue (6.7% per year) is forecast to grow slower than the Polish market (7% per year).
High Growth Revenue: NEU's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEU's Return on Equity is forecast to be low in 3 years time (18.1%).
How has NEUCA performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEU has high quality earnings.
Growing Profit Margin: NEU's current net profit margins (1.5%) are higher than last year (1.4%).
Past Earnings Growth Analysis
Earnings Trend: NEU's earnings have grown by 3.1% per year over the past 5 years.
Accelerating Growth: NEU's earnings growth over the past year (16.3%) exceeds its 5-year average (3.1% per year).
Earnings vs Industry: NEU earnings growth over the past year (16.3%) exceeded the Healthcare industry -0.3%.
Return on Equity
High ROE: NEU's Return on Equity (18.4%) is considered low.
How is NEUCA's financial position?
Financial Position Analysis
Short Term Liabilities: NEU's short term assets (PLN2.2B) do not cover its short term liabilities (PLN2.3B).
Long Term Liabilities: NEU's short term assets (PLN2.2B) exceed its long term liabilities (PLN253.6M).
Debt to Equity History and Analysis
Debt Level: NEU's debt to equity ratio (41.2%) is considered high.
Reducing Debt: NEU's debt to equity ratio has increased from 37.1% to 41.2% over the past 5 years.
Debt Coverage: NEU's debt is well covered by operating cash flow (21%).
Interest Coverage: NEU's interest payments on its debt are well covered by EBIT (39.4x coverage).
What is NEUCA current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NEU's dividend (1.44%) isn’t notable compared to the bottom 25% of dividend payers in the Polish market (1.86%).
High Dividend: NEU's dividend (1.44%) is low compared to the top 25% of dividend payers in the Polish market (5.69%).
Stability and Growth of Payments
Stable Dividend: NEU's dividends per share have been stable in the past 10 years.
Growing Dividend: NEU's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.9%), NEU's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: NEU's dividends in 3 years are forecast to be well covered by earnings (27.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Piotr Sucharski serves as General Director at NEUCA S.A. and has been its President of The Board of Directors since January 2009. He served as Financial Director of Neuca Spolka Akcyjna. He worked with...
CEO Compensation Analysis
Compensation vs Market: Piotr's total compensation ($USD381.26K) is about average for companies of similar size in the Polish market ($USD507.64K).
Compensation vs Earnings: Piotr's compensation has been consistent with company performance over the past year.
|Chairman of the Supervisory Board||no data||zł539.00k||29.1% |
|Member of the Supervisory Board||11.42yrs||zł132.00k||0.0033% |
|Deputy Chairman of the Supervisory Board||no data||zł157.00k||25.58% |
|Member of the Supervisory Board||9.42yrs||zł25.00k||no data|
|Member of Supervisory Board||3.08yrs||zł44.00k||no data|
|Member of Supervisory Board||no data||zł43.00k||no data|
Experienced Board: NEU's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.
NEUCA S.A.'s company bio, employee growth, exchange listings and data sources
- Name: NEUCA S.A.
- Ticker: NEU
- Exchange: WSE
- Founded: 1990
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: zł2.720b
- Shares outstanding: 4.37m
- Website: https://neuca.pl
Number of Employees
- NEUCA S.A.
- ul. Szosa Bydgoska 35-37
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NEU||WSE (Warsaw Stock Exchange)||Yes||Common Stock||PL||PLN||Nov 2004|
|0MJR||LSE (London Stock Exchange)||Yes||Common Stock||GB||PLN||Nov 2004|
NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and T...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/01 18:01|
|End of Day Share Price||2020/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.